Excelente respuesta clínica a largo plazo con rivaroxabán en vasculopatía livedoide. Un estudio retrospectivo
Open Access
- 14 September 2022
- journal article
- letter
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (2) , 183-185
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Rivaroxaban for treatment of livedoid vasculopathy: A systematic reviewDermatologic Therapy, 2021
- Livedoid vasculopathy in 75 Brazilian patients in a single‐center institution: Clinical, histopathological and therapy evaluationDermatologic Therapy, 2021
- Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatmentJournal of the European Academy of Dermatology and Venereology, 2019
- Vasculopatía livedoide tratada con rivaroxabán. Potenciales usos de los nuevos anticoagulantes orales para el dermatólogoActas Dermo-Sifiliograficas, 2018
- Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxabanJournal of the European Academy of Dermatology and Venereology, 2017
- Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathyJournal of Pain Research, 2017
- Case series of recalcitrant livedoid vasculopathy treated with rivaroxabanClinical and Experimental Dermatology, 2016
- Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trialThe Lancet Haematology, 2016
- Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathyBritish Journal of Dermatology, 2013